Harvard Bioscience (HBIO) Common Equity (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Common Equity data on file, last reported at $10.0 million in Q1 2026.

• On a quarterly basis, Common Equity fell 32.28% year-over-year to $10.0 million in Q1 2026; TTM through Mar 2026 was $10.0 million, a 32.28% decrease from a year earlier, with the FY2025 full-year figure at $13.7 million, down 78.32% from the prior year.
• Common Equity for Q1 2026 stood at $10.0 million, down from $13.7 million in the prior quarter.
• Over the last five years, Common Equity for HBIO reached as high as $77.5 million in Q2 2022 and fell as low as $10.0 million in Q1 2026.
• Historically, Common Equity has averaged $54.6 million across 5 years, with a median of $68.8 million in 2024.
• Across the five-year window, Common Equity gained 3.21% in 2023 and plunged 78.46% in 2025, its largest moves.
• Year by year, Common Equity stood at $72.2 million in 2022, then increased by 1.18% to $73.1 million in 2023, then fell by 13.32% to $63.3 million in 2024, then slumped by 78.32% to $13.7 million in 2025, then fell by 26.85% to $10.0 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $10.0 million in Q1 2026, $13.7 million in Q4 2025, and $14.1 million in Q3 2025.